Why the study?
Venous thromboses are a well-documented complication of pancreatic cancer, but there is less awareness and focus on arterial events such as ischaemic stroke and myocardial infarction.
Case Report (n=1)
This case highlights the aggressive, refractory nature of Trousseau syndrome and the potential inadequacy of DOACs like apixaban in preventing recurrent arterial and venous thromboembolism in mucin-producing adenocarcinomas.
Suggests DOAC caution in refractory Trousseau syndrome; single case leaves open optimal antithrombotic strategies for mucin-producing cancers.
Pancreatic cancer is a malignancy strongly associated with cancer-related hypercoagulability. Venous thromboses are a well-documented complication of pancreatic cancer, but there is less awareness and focus on arterial events such as ischaemic stroke and myocardial infarction. We present the case of a patient who was diagnosed with ischaemic stroke preceding a diagnosis of an occult metastatic pancreatic malignancy and concurrent pulmonary embolism. Despite treatment with therapeutic doses of direct oral anticoagulation, the patient subsequently developed recurrent bilateral ischaemic strokes. This case highlights the challenges of managing mixed venous and arterial thromboembolic disease in patients with pancreatic cancer and illustrates the aggressive, refractory nature of Trousseau syndrome.
No takes yet. Share an insight, caveat, or question.
Aung et al. (2025) conducted a case report in Trousseau Syndrome (Metastatic Pancreatic Cancer with Recurrent Ischaemic Strokes and Pulmonary Embolism) (n=1). Apixaban was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: